Study Title

claritypharmaceuticals

Positron Emission Tomography Using 64Cu-SAR-bisPSMA in Participants With High-risk Prostate Cancer Prior to Radical Prostatectomy: A Prospective, Single-arm, Multi-center, Blinded-review, Phase 3 Diagnostic Performance Study

Study Details

Description:

The aim for this study is to assess the diagnostic performance of 64Cu-SAR-bisPSMA PET to detect regional nodal metastases.

Contacts:

Clarity Pharmaceuticals

clinicaltrials@claritypharmaceuticals.com

+61 (0) 2 9209 4037

Patient Education

Patient Education Not Yet Provided

Publications

Publications Not Yet Provided